)
Niagen Bioscience (NAGE) investor relations material
Niagen Bioscience 18th Annual Southwest IDEAS Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.NAD science and research
NAD supports cellular energy metabolism and damage repair; high levels were described as improving mitochondrial output and cellular resilience.
R&D focus includes 100+ patents, 500+ published studies, 52 peer-reviewed human clinical studies on nicotinamide riboside, and 300+ research collaborations.
A 200-participant, six-month Tru Niagen study found slowing or reversal of biological age on five of seven epigenetic clocks, according to the presentation.
Commercial products and growth opportunities
Tru Niagen is positioned as a leading single-ingredient supplement; ~60% of sales came through Amazon and Shopify, with ~$20M wholesale and ~$25M ingredient sales last year.
Injection and IV sales were estimated at $5M-$10M; distribution included 1,700 U.S. clinics and a recently launched at-home injection kit, with large telehealth discussions underway.
The U.S. NAD IV market was estimated at $500M; a Restore pilot across 200 stores made Niagen its flagship ingredient, with management optimistic about 2027 growth.
NanoCloud skincare was described as penetrating skin and elevating NAD in damaged skin; Estée Lauder discussions could lead to a Niagen product in the next few months.
Pharmaceutical pipeline and funding plans
NB4168, a proprietary prodrug, is being developed for rare diseases including ataxia-telangiectasia; two positive Phase II studies used Tru Niagen, while the program has shifted to NB4168.
Management estimated $30M-$40M of incremental spending over ~4 years to reach drug approval; licensing, co-financing, or spinoff arrangements may come sooner.
Management plans another 6-12 months of work before pursuing partnerships more aggressively; interested parties have approached, but current terms were viewed as insufficiently compelling.
Rare-disease approval may bring a transferable priority-review voucher; management cited recent voucher sales above $200M and potential orphan-drug pricing of $400,000-$1M per year.
- TRU NIAGEN drove 49% FY sales growth, while losses widened and break-even remained a 2019/20 target.NAGE
Q4 2018 - TRU NIAGEN drove 47% FY sales growth as margins improved and global expansion continued.NAGE
Q4 2019 - Q4 growth and stronger margins advanced the path toward break-even.NAGE
Q4 2020 - Consumer expansion and rare-disease development anchor a four-part growth strategy.NAGE
A.G.P. Virtual Consumer Showcase - A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGE
Q3 2026 - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGE
LD Micro 20th Annual Main Event Conference - Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE
17th Annual Midwest IDEAS Conference - Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGE
Canaccord Genuity's 46th Annual Growth Conference
)
)
)
)
)
)
)
)